Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing significant cardiovascular events (MACE-3) among more than 13,000 adults with cardiovascular disease and type 2 diabetes. Mounjaro reported higher decreases in body weight (−11.43 kg vs. −4.65 kg), A1C (1.73% vs. 0.90%), and a slowed decline in kidney function by 3.54 mL/min/1.73 m² at 36 months, along with a drop in all-cause mortality by 16%.
Mounjaro, a GIP/GLP-1 dual receptor agonist, performed better than Trulicity, a GLP-1 agonist, in several important endpoints in the longest and most extensive tirzepatide trial to date. The 4.5-year research, which covered 30 countries, reaffirmed Mounjaro’s tolerability and safety. According to a predetermined indirect analysis, Mounjaro decreased all-cause mortality by 39% and MACE-3 by 28% when compared to a placebo. Eli Lilly and Company will discuss all of the findings at the 2025 EASD meeting and aims to submit regulatory applications by year’s end.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None.
